Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Tempus AI posts first GAAP profit, boosts 2026 revenue forecast to $1.6B with FDA approval aiding growth
TEM
$61.02
+$11.66 +23.62%

Tempus AI posts first GAAP profit, boosts 2026 revenue forecast to $1.6B with FDA approval aiding growth

Company Fundamentals
18 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Tempus AI reported its first GAAP profit driven by growth in its data business and improved operating leverage from oncology volume and high-margin products. The company raised its 2026 revenue guidance to $1.595–$1.605 billion, a 25% increase year-over-year. FDA approval for its xT CDx test and higher pricing for xF liquid biopsy are expected to add around $400 million in revenue by 2028. The recent acquisition of Personalis aims to strengthen its position in minimal residual disease (MRD) testing. Despite a relatively high valuation, the company’s strong data assets and growth prospects support a 'Buy' rating.

More News (TEM)

Tempus AI's $1.5B buy of Personalis validated by Moderna-Merck cancer vaccine success.

Tempus AI's $1.5B buy of Personalis validated by Moderna-Merck cancer vaccine success.

Tempus AI agreed to acquire Personalis for $1.5 billion in a stock deal, gaining access to Personalis's ultrasensitive cancer DNA detection test, NeXT Personal. This technology supports a personalized mRNA cancer vaccine by Moderna and Merck, which r...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App